Seven Fleet Capital Management LP Has $26.78 Million Holdings in Pharvaris N.V. $PHVS

Seven Fleet Capital Management LP lifted its stake in Pharvaris N.V. (NASDAQ:PHVS) by 144.6% during the second quarter, Holdings Channel.com reports. The fund owned 774,501 shares of the company’s stock after buying an additional 457,804 shares during the period. Pharvaris accounts for approximately 4.4% of Seven Fleet Capital Management LP’s holdings, making the stock its 4th largest holding. Seven Fleet Capital Management LP’s holdings in Pharvaris were worth $26,782,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of PHVS. PSP Research LLC bought a new stake in shares of Pharvaris during the 4th quarter worth approximately $569,000. DV Trading LLC acquired a new position in Pharvaris during the first quarter worth $4,067,000. ADAR1 Capital Management LLC bought a new stake in Pharvaris during the second quarter worth $3,649,000. 5AM Venture Management LLC bought a new stake in Pharvaris during the second quarter worth $27,581,008,000. Finally, Commodore Capital LP lifted its stake in Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after acquiring an additional 29,525 shares during the last quarter.

Insider Buying and Selling at Pharvaris

In other news, insider Anna Nijdam sold 2,670 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $30.87, for a total transaction of $82,422.90. Following the completion of the sale, the insider directly owned 46,275 shares in the company, valued at approximately $1,428,509.25. This represents a 5.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the transaction, the director owned 315,167 shares in the company, valued at $11,185,276.83. The trade was a 8.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 121,325 shares of company stock worth $4,270,425. 11.84% of the stock is currently owned by company insiders.

Pharvaris Stock Down 0.6%

Shares of NASDAQ:PHVS opened at $37.00 on Thursday. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $38.13. The stock has a market cap of $2.42 billion, a PE ratio of -12.13 and a beta of -2.31. The business has a 50 day moving average of $34.47 and a 200-day moving average of $30.64.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities research analysts expect that Pharvaris N.V. will post -3.15 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on PHVS. New Street Research set a $60.00 price objective on shares of Pharvaris in a research note on Friday, August 14th. Royal Bank Of Canada raised their target price on shares of Pharvaris from $51.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Morgan Stanley lifted their price target on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a report on Thursday, June 25th. Guggenheim boosted their price target on Pharvaris from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Finally, Wells Fargo & Company initiated coverage on Pharvaris in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.08.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.